Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with OTEZLA in P-III ESTEEM trial

 Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with OTEZLA in P-III ESTEEM trial

Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with OTEZLA in P-III ESTEEM trial

Shots:

  • Results: ESTEEM 1, 2: NAPSI@32wk (31.3% vs 15.5), DLQI @16wks. (28.7% vs 8.1%); UNVEIL: NAPSI@32wks. (36.2% vs 37.2%), DLQI@16wks. (23.7% vs 10.6%)
  • Though, Post-hoc analysis revealed that OTEZLA was not able to achieve PASi75@32/52wks
  • A 5-year extension study of ESTEEM 1 and 2 is ongoing. OTEZLA (apremilast) (PDE4i) marketed as 30 mg PO indicated for the treatment of patients with moderate-to-severe plaque psoriasis
  • Another study UNVEIL is assessing safety and efficacy of OTEZLA in patients with ratio (2:1) administering either 30 mg bid or PBO with moderate plaque psoriasis
  • ESTEEM (1(PSAI 75), 2(PSAI 50)) involves assessing of OTEZLA with changes in scalp and nail psoriasis & QoL in patients with moderate to severe plaque & nail psoriasis in ratio (2:1) administering either 30 mg bid or PBO for 16 wks. after an initial five-day titration period

Click here to read full press release/ article | Ref: Celgene | Image: The street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post